Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020198695 - COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY

Publication Number WO/2020/198695
Publication Date 01.10.2020
International Application No. PCT/US2020/025511
International Filing Date 27.03.2020
IPC
A61K 47/64 2017.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
50the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
51the non-active ingredient being a modifying agent
62the modifying agent being a protein, peptide or polyamino acid
64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
Applicants
  • SIGILON THERAPEUTICS, INC. [US]/[US]
Inventors
  • BARNEY, Lauren Emily
  • BEAUREGARD, Michael
  • CARMONA, Guilaume
  • GONZALES, Francisco Caballero
  • HEIDEBRECHT, Richard
  • JOHNSTON, Erika Ellen
  • MILLER, Robert James
  • O'CONNER, Owen
  • OBERLI, Matthia Alexander
  • PERITT, David
  • SEWELL, Jared A.
  • SMITH, Devyn McKinley
  • VEISEH, Omid
  • WOTTON, Paul Kevin
  • YIN, Zoe
Agents
  • COLLAZO, Diana M
  • COLLAZO, Diana, M.
Priority Data
62/824,96327.03.2019US
62/907,38627.09.2019US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) COMPOSITIONS, DEVICES AND METHODS FOR FACTOR VII THERAPY
(FR) COMPOSITIONS, DISPOSITIFS ET MÉTHODES POUR THÉRAPIE ASSOCIÉE AU FACTEUR VII
Abstract
(EN)
Described herein are RPE cells engineered to secrete a FVII protein, as well as compositions, pharmaceutical preparations, and implantable devices comprising the engineered RPE cells, and methods of making and using the same for treating a patient with hemophilia or FVII deficiency.
(FR)
L'invention concerne des cellules RPE modifiées pour sécréter une protéine de FVII, ainsi que des compositions, des préparations pharmaceutiques et des dispositifs implantables comprenant les cellules RPE modifiées, et des méthodes de fabrication et d'utilisation de celles-ci pour traiter un patient souffrant d'hémophilie ou d'une déficience du FVII.
Latest bibliographic data on file with the International Bureau